Drug Eluting Pantera® LUX Catheter Registry

2014-07-23 21:09:55 | BioPortfolio


Evaluation of the safety and efficacy of the Pantera® Lux Paclitaxel releasing balloon for coronary arteries in daily clinical practice.


All patients are treated with the Pantera® Lux Paclitaxel releasing balloon. The indication is in-stent restenosis in a coronary artery.

There will be follow-up assessments at 1, 6 and 12 months after coronary intervention. The clinical status will be evaluated at the different follow-up time points.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


In-Stent Restenosis


Herz-Kreislauf-Zentrum, Segeberger Kliniken GmbH
Bad Segeberg




Biotronik AG

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:09:55-0400

Clinical Trials [818 Associated Clinical Trials listed on BioPortfolio]

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent

To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.

The Valentines Trial

The primary objective of this multi-center, international, short term registry is to assess clinical success and efficacy of the paclitaxel eluting balloon treatment for in-stent restenosi...

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

The purpose of this study is to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following ...

Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period

Interventional, prospective, non-randomized, non-comparative, open and multicentric study of patients with everolimus-eluting stent " Xience V® " implanted in the treatment of restenosis ...

Metal Allergy In-Stent Restenosis Study

In-stent restenosis remains one of the most challenging problems in patients after coronary artery angioplasty. Angiographically, it is discovered in 10% of the patients after drug-eluting...

PubMed Articles [470 Associated PubMed Articles listed on BioPortfolio]

The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis.

In the current meta-analysis, we aim to assess the effect of high-sensitive C-reactive protein (hs-CRP) on in-stent restenosis (ISR) outcome in patients receiving stent implantation.

Calcified neoatherosclerosis causing in-stent restenosis: prevalence, predictors, and implications.

Neoatherosclerosis has emerged as a major cause of in-stent restenosis (ISR). Although this entity has been described as a unique process, optical coherence tomography (OCT) enables depiction of disti...

Management of isolated femoropopliteal in-stent restenosis.

The optimal catheter-directed therapy for femoropopliteal in-stent restenosis (ISR) remains controversial with limited durability. The natural history of untreated ISR is not well characterized. We ev...

Angiographic and clinical performance of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in patients with in-stent restenosis- the BIOLUX randomized controlled trial.

The optimal treatment of in-stent restenosis (ISR) remains unknown. This study evaluates the efficacy and safety of a paclitaxel coated balloon compared to a 2nd generation sirolimus eluting stent in ...

Modelling chemistry and biology after implantation of a drug-eluting stent. Part Ⅱ: Cell proliferation.

The aim of a drug eluting stent is to prevent restenosis of arteries following percutaneous balloon angioplasty. A long term goal of research in this area is to use modelling to optimise the design of...

Medical and Biotech [MESH] Definitions

Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.

Surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent.

Postoperative hemorrhage from an endovascular AORTIC ANEURYSM repaired with endoluminal placement of stent grafts (BLOOD VESSEL PROSTHESIS IMPLANTATION). It is associated with pressurization, expansion, and eventual rupture of the aneurysm.

A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of esophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (JAMA 1995;273(23):1824-30)

More From BioPortfolio on "Drug Eluting Pantera® LUX Catheter Registry"

Quick Search


Relevant Topic

A stent is a small mesh tube that's used to treat narrow or weak arteries. Arteries are blood vessels that carry blood away from your heart to other parts of your body.  A stent is placed in an artery as part of a procedure called angioplasty. &...

Searches Linking to this Trial